Clinical Trial

Pharmacokinetics and Safety of M107 Orally Disintegrating Tablet in Healthy Adults

Completed Phase 1
View on ClinicalTrials.gov →
Summary
Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of lobeglitazone administered as M107 Orally Disintegrating Tablet and Duvie tablet in healthy adult participants under fasted and fed conditions.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-30; most recent amendment 2026-04-24.
Status change: Recruiting → Completed 2026-04-24
Status change: Not Yet Recruiting → Recruiting 2025-07-24
Trial Details
NCT Number NCT07056517
Lead Sponsor Aclipse Two Inc.
Conditions Healthy
Enrollment 21 participants
Start Date 2025-07-11
Primary Completion 2025-09-22 (estimated)
Study Completion 2025-09-22 (estimated)
Updated on ClinicalTrials.gov 2026-04-29